Liquidia Technologies used its slot at the Wells Fargo 21st Annual Healthcare Conference to detail a growth trajectory that aims for a $1 billion annualized run‑rate, equivalent to $250 million in quarterly revenue, by the fourth quarter of 2025. The company reported Q2 2026 revenue of $170 million from its inhaled prostacyclin product YUTREPIA, with EBITDA around $100 million and net income near $80 million. Cash added to the balance sheet in the same quarter was $60 million, and revenue has risen by roughly $40 million each quarter over the past three quarters.
YUTREPIA, launched in May 2025, splits its prescriptions evenly between pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). About 75 % of patients are treatment‑naïve, while the remaining 25 % are switches from existing prostacyclins such as Tyvaso DPI and Remodulin. The sales force was expanded by 33 % in the latest quarter to target community‑based prescribers. Liquidia estimates the addressable PH‑ILD market at over 60,000 patients, representing a $3‑5 billion long‑term opportunity, while the PAH market exceeds $3 billion.
Clinical data from the ASCENT study of YUTREPIA showed progressive improvements in the six‑minute walk test: a 21‑meter gain at eight weeks, 31 meters at 16 weeks and 41 meters at 24 weeks, corresponding to dose equivalents of 15, 18 and 21 breaths of Tyvaso respectively. Cough incidence remained low and transient even at higher doses. The product leverages PRINT technology to create uniform particles that bypass the upper airway for deep‑lung deposition.
The pipeline’s next milestone is L606, a liposome‑encapsulated treprostinil formulation delivered twice daily via a Vectura nebulizer. The Phase III INSPIRE trial for PH‑ILD began enrolling patients in Q2 2026, targeting roughly 350 participants across more than 20 countries, with top‑line data expected in 2029. An open‑label U.S. study reported a 14 % drug‑related cough rate at 48 weeks and a 21 % rate of titration to doses equivalent to 30 or more Tyvaso breaths, while achieving a seven‑fold reduction in Cmax versus standard dosing.
Additional studies in the pipeline include an open‑label trial in idiopathic and progressive pulmonary fibrosis, a registrational PH‑COPD study slated for late 2027 targeting up to 300,000 U.S. patients, and a Phase II dose‑finding trial in systemic sclerosis with Raynaud’s phenomenon starting in 2026. Liquidia also plans transition studies from oral to inhaled and IV to inhaled prostacyclins, alongside real‑time hemodynamic assessments.
The company faces a pending patent litigation trial scheduled for June 2025, with a ruling still awaited after 14 months of deliberation. Management remains confident that the legal outcome will not impede the projected commercial expansion and pipeline progress.
